Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

[Therapy of multiple myeloma. What is confirmed?].

Peest D, Ganser A, Einsele H.

Internist (Berl). 2013 Dec;54(12):1434, 1436-8, 1440-2. doi: 10.1007/s00108-013-3323-7. Review. German.

PMID:
24201762
2.
3.

Targeted therapy of multiple myeloma.

Kyle RA.

Hematology. 2012 Apr;17 Suppl 1:S125-8. doi: 10.1179/102453312X13336169156339.

PMID:
22507799
4.

Multiple myeloma. An update on diagnosis and management.

Kyle RA.

Acta Oncol. 1990;29(1):1-8. Review.

PMID:
2178649
5.

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2017 Feb;15(2):230-269.

PMID:
28188192
6.

Multiple Myeloma. Diagnostic challenges and standard therapy.

Kyle RA.

Semin Hematol. 2001 Apr;38(2 Suppl 3):11-4. Review.

PMID:
11309703
7.

Tailoring initial treatment for newly diagnosed, transplantation-eligible multiple myeloma.

Stadtmauer EA.

Oncology (Williston Park). 2010 Mar;24(3 Suppl 2):7-13.

8.

Induction therapy in multiple myeloma.

Harousseau JL.

Hematology Am Soc Hematol Educ Program. 2008:306-12. doi: 10.1182/asheducation-2008.1.306.

PMID:
19074101
9.

Treatment of newly diagnosed multiple myeloma.

Palumbo A, Magarotto V, Larocca A, Bringhen S, Falco P, Di Raimondo F, Baldini L, Boccadoro M.

Curr Hematol Malig Rep. 2008 Apr;3(2):107-14. doi: 10.1007/s11899-008-0016-8.

PMID:
20425454
10.

[Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].

Hayashi T, Yasui H, Kawakami K, Ikeda H, Takahashi F, Kobayashi T, Nishimura S, Ishida T, Imai K, Shinomura Y.

Rinsho Ketsueki. 2011 Mar;52(3):136-41. Japanese.

PMID:
21471701
11.

Multiple myeloma maintenance therapy: a review of the pharmacologic treatment.

Shank BR, Brown VT, Schwartz RN.

J Oncol Pharm Pract. 2015 Feb;21(1):36-51. doi: 10.1177/1078155213514468. Epub 2014 Jan 6. Review.

PMID:
24395544
12.

Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.

Hobeika L, Self SE, Velez JC.

BMC Nephrol. 2014 Sep 30;15:156. doi: 10.1186/1471-2369-15-156.

13.

[Clincal features and treatment of multiple myeloma].

Mai EK, Goldschmidt H.

Radiologe. 2014 Jun;54(6):538-44. doi: 10.1007/s00117-013-2625-z. German.

PMID:
24849305
14.

Multiple myeloma.

Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC.

Lancet. 2009 Jul 25;374(9686):324-39. doi: 10.1016/S0140-6736(09)60221-X. Epub 2009 Jun 21. Review.

PMID:
19541364
15.

Current and emerging treatments for multiple myeloma.

Schwartz RN, Vozniak M.

J Manag Care Pharm. 2008 Sep;14(7 Suppl):12-9. Review.

16.

Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.

Reece D, Imrie K, Stevens A, Smith CA; Hematology Disease Site Groupof Cancer Care Ontario’s Program in Evidence-based Care.

Curr Oncol. 2006 Oct;13(5):160-72.

17.

Multiple myeloma.

Raje N, Anderson KC.

Curr Treat Options Oncol. 2000 Apr;1(1):73-82. Review.

PMID:
12057063
18.

Multiple myeloma.

Bladé J, Cibeira MT, Fernández de Larrea C, Rosiñol L.

Ann Oncol. 2010 Oct;21 Suppl 7:vii313-9. doi: 10.1093/annonc/mdq363. Review.

PMID:
20943635
19.

Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.

Zou D, An G, Zhu G, Wang J, Shi L, Meng H, Xu Y, Sui W, Deng S, Zhan F, Qiu L.

Biol Blood Marrow Transplant. 2014 Mar;20(3):319-25. doi: 10.1016/j.bbmt.2013.11.022. Epub 2013 Dec 1.

20.

Stem cell transplantation for multiple myeloma.

Gasparetto C.

Cancer Control. 2004 Mar-Apr;11(2):119-29. Review.

Supplemental Content

Support Center